Literature DB >> 18239937

A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid.

Priscilla Verhulst1, Patrick Devos, Sébastien Aubert, David Buob, Isaac Cranshaw, Christine Do Cao, François Pattou, Bruno Carnaille, Jean-Louis Wemeau, Emmanuelle Leteurtre.   

Abstract

Morphologic examination is the gold standard for diagnosing papillary thyroid carcinoma (PTC). This diagnosis, especially for the follicular variant, may be variable even among experts. Our objective was to analyze the frequency of PTC microscopic criteria in a series of thyroid tumors including follicular adenoma (FA) and PTC to build a score which could constitute a novel way for microscopic analysis of such thyroid tumors. Sixty-six PTC and 66 FA were matched for age, sex, and thyroiditis. Two independent observers delineated the classical PTC microscopic criteria. PTC microscopic criteria were variably expressed in individual tumors. Under univariate analysis, all criteria were significantly more frequent in PTC than in FA (p<0.05). Under multivariate analysis, the most important criteria were: dark staining colloid >25%, nuclear grooves, enlarged nuclei, ovoid nuclei >5% of tumor cells, and lack of polarization. Using linear discriminant analysis, these five criteria allowed us to build a scaled score. The score proposed did not allow the making of a definite distinction between FA and PTC in routine practice. It represents the variety of microscopic presentations of FA and PTC on the basis of a statistical analysis and could help in further evaluation of immunohistochemical or molecular markers.

Entities:  

Mesh:

Year:  2008        PMID: 18239937     DOI: 10.1007/s00428-008-0577-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  34 in total

1.  Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma.

Authors:  Andrew A Renshaw; Edwin W Gould
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

2.  Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma.

Authors:  John K C Chan
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

Review 3.  RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 5.  Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  Expert Rev Mol Diagn       Date:  2005-07       Impact factor: 5.225

6.  Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Authors:  P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

7.  Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Authors:  Nobuki Nakamura; Lori A Erickson; Long Jin; Sabine Kajita; Heyu Zhang; Xiang Qian; Kandelaria Rumilla; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

8.  Discrimination of benign and malignant thyroid nodules by molecular profiling.

Authors:  David J Finley; Baixin Zhu; Catherine B Barden; Thomas J Fahey
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

9.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

10.  Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.

Authors:  J E Barroeta; Z W Baloch; P Lal; T L Pasha; P J Zhang; V A LiVolsi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

View more
  1 in total

1.  Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.

Authors:  Vanessa Arcolia; Fabrice Journe; Florence Renaud; Emmanuelle Leteurtre; Hans-Joachim Gabius; Myriam Remmelink; Sven Saussez
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.